Crystal Lake, Illinois-(BUSINESS WIRE)-Aptar Group, Inc. (New York Stock Exchange: ATR), a global leader in drug delivery, consumer product distribution and active packaging solutions, announced that its Activ-Film™ technology has been selected for use To protect a new SARS rapid antigen test against COVID-19, the test has recently received an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA).
The QuickVue® SARS Antigen Test is an instant care rapid antigen test developed by Quidel® Corporation, a leading manufacturer of diagnostic healthcare solutions, and can provide test results within 10 minutes. The visual reading test does not require any auxiliary equipment and provides extended access to affordable and accurate COVID-19 testing, which will help meet the urgent testing needs of the global economy, including testing needs for school systems and rural areas .
Aptar CSP Technologies’ Activ-Film™ technology has been integrated into the diagnostic kit to protect against humidity and other environmental conditions that may affect the accuracy of the test. Activ-Film™ utilizes Aptar’s proprietary three-phase Activ-Polymer™ technology, which provides custom engineered protection in a variety of configurations, such as Activ-Vial™ for accommodating a diagnostic dipstick and Activ integrated in a diagnostic box -Tab. This active packaging technology based on materials science is currently used to protect various electrochemical, lateral flow and molecular diagnostic test kits on the market today.
Aptar President and CEO Stephan B. Tanda said: “We are very pleased to work with Quidel® Corporation on this critical diagnostic tool and help bring the QuickVue® SARS antigen test to the market.” “Our materials science Activ-Film ™ technology protects test strips and helps provide fast, reliable results. We will continue to perform by providing solutions that protect critical COVID-19 diagnostic kits, as well as solutions for the distribution of medicines and consumer products that millions of people need every day The purpose and responsibility to society.”
Badre Hammond, Vice President of Commercial Operations at Aptar CSP Technologies, concluded: “As we continue to respond to the COVID-19 crisis, this game-changing solution will help meet the urgent need for COVID-19 testing in communities around the world. We are committed to To leverage our materials science expertise to enable our partners to meet the ongoing demand for innovative healthcare solutions to help improve and save lives.”
Aptar is a global leader in the design and manufacture of various drug delivery, consumer product distribution and active substance solutions. Aptar’s innovative solutions and services serve a variety of end markets, including pharmaceuticals, beauty, personal care, households, food and beverages. Aptar uses insight, design, engineering and science and technology to create distribution, quantitative and protective packaging technology for many world-leading brands, thereby bringing benefits to patients and consumers’ lives, appearance, health, and homes worldwide. Changes in meaning. Aptar is headquartered in Crystal Lake, Illinois, and has 13,000 dedicated employees in 20 countries. For more information, please visit www.aptar.com.
This press release contains forward-looking statements. Express or future or conditional verbs (such as “will”) are intended to identify such forward-looking statements. Forward-looking statements are made in accordance with the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are based on our beliefs, assumptions and information we currently have. Therefore, due to known or unknown risks and uncertainties in our operations and business environment, our actual results may differ materially from those expressed or implied in forward-looking statements, including but not limited to: successful integration of acquisitions; The regulatory environment; and competition, including technological progress. For more information about these and other risks and uncertainties, please refer to our filing with the US Securities and Exchange Commission, including “Risk Factors” and “Management’s Discussion and Analysis of Financial Conditions and Operating Results on Form 10-K.” Discussion under. And Form 10-Q. We assume no obligation to update any forward-looking statements due to new information, future events or other reasons.
Investor Relations Contact: Matt DellaMaria matt.dellamaria@aptar.com 815-479-5530 Media Contact: Katie Reardon katie.reardon@aptar.com 815-479-5671
Investor Relations Contact: Matt DellaMaria matt.dellamaria@aptar.com 815-479-5530 Media Contact: Katie Reardon katie.reardon@aptar.com 815-479-5671
Post time: Feb-25-2021